HC Wainwright Has Bullish Forecast for CRBU Q2 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Stock analysts at HC Wainwright upped their Q2 2026 earnings per share estimates for Caribou Biosciences in a research note issued on Monday, May 11th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.29) per share for the quarter, up from their prior estimate of ($0.34). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.25) per share. HC Wainwright also issued estimates for Caribou Biosciences’ Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.36) EPS and FY2026 earnings at ($1.23) EPS.

Other equities analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a research note on Monday, April 20th. Truist Financial upgraded Caribou Biosciences to a “strong-buy” rating in a research note on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $8.67.

Caribou Biosciences Price Performance

Shares of CRBU stock opened at $2.03 on Wednesday. The business has a 50 day moving average of $1.97 and a two-hundred day moving average of $1.86. Caribou Biosciences has a 52 week low of $0.77 and a 52 week high of $3.54. The company has a market cap of $201.34 million, a P/E ratio of -1.43 and a beta of 2.27.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.07. The business had revenue of $2.40 million during the quarter, compared to the consensus estimate of $2.21 million. Caribou Biosciences had a negative return on equity of 84.17% and a negative net margin of 1,189.14%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Creative Planning purchased a new position in Caribou Biosciences during the 2nd quarter worth approximately $25,000. Bronte Capital Management Pty Ltd. purchased a new position in Caribou Biosciences during the 4th quarter worth approximately $25,000. R Squared Ltd purchased a new position in Caribou Biosciences during the 3rd quarter worth approximately $29,000. Hudson Bay Capital Management LP purchased a new position in Caribou Biosciences during the 2nd quarter worth approximately $30,000. Finally, Westmount Partners LLC purchased a new position in Caribou Biosciences during the 1st quarter worth approximately $37,000. Institutional investors own 77.51% of the company’s stock.

More Caribou Biosciences News

Here are the key news stories impacting Caribou Biosciences this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates for Caribou Biosciences across multiple periods, including Q2 2026, Q3 2026, Q4 2026 and FY2026, and reiterated a Buy rating with an $11 price target. That kind of analyst support can help sentiment in CRBU shares. CRBU stock page
• Positive Sentiment: Caribou announced that two abstracts were accepted for oral presentations at the 2026 European Hematology Association meeting, covering its lead programs vispa-cel and CB-011. Oral presentations at a major medical conference can raise visibility for the pipeline and suggest ongoing scientific progress. EHA presentation announcement
• Neutral Sentiment: Brookline Capital Markets also updated several long-term earnings estimates for CRBU, with some near-term cuts and some longer-dated changes. These revisions matter for valuation, but the impact is mixed because the company is still expected to post losses for the foreseeable future.
• Negative Sentiment: Despite the analyst optimism, Caribou Biosciences is still projected to report negative EPS this year and next, underscoring continued losses and the likelihood that investors will focus on execution and funding needs rather than current profits.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.